Abstract
IntroductionChanges in the American Joint Commission on Cancer staging for breast cancer occurred when the 5th Edition was updated to the 6th Edition. ObjectiveTo investigate how these changes affected stage and survival. Methods3127 cases of breast cancer were restaged. ResultsLate stages increased from 27.7% to 38.1%. The five-year survival improved in Stage 2 (82.9–86.1%) and Stage 3 (50.6–59%). DiscussionStage shift leads to an erroneous impression that women are presenting with later stages and stage-specific survival is improving. ConclusionStandardizing cancer staging is important when reporting stage and survival in different time periods.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
